Enveric Biosciences Inc (NASDAQ:ENVB) currently has a daily average trading volume of 36.36K but it saw 1415302 shares traded in last market. With a market cap of 2.70M USD, the company’s current market price of $3.90 came falling about -9.30 while comparing to the previous closing price of $4.30. In past 52 weeks, the stock remained buoying in the range of price level as high as $43.80 and as low as $3.88. In the recent trading on the day, stock has struck highest price mark of $3.9 while lowest mark touched by it was $4.83.
Taking a look at 20-day trading activity of Enveric Biosciences Inc (ENVB) gives us an average price of $5.36, while its current price level is -91.10% below from 52-week high level whereas it is 0.50% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.19 while that of 200 days or SMA-200 reads an average of $8.13. A closer look into the stock’s movement over the week reveals that its volatility is standing at 14.63% during that period while stretching the period over a month that decreases to 13.52%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 32.71 which implies that the stock is in neutral territory.
Over the week, ENVB’s stock price is moving -21.92% down while it is -25.07% when we observe its performance for the past one month. Year-to-date it is -27.46% down and over the past year, the stock is showing a downside performance of -71.11%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Enveric Biosciences Inc’s total number of outstanding shares is 0.60M with 6.93% of that held by the insiders while 7.06% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -249.45% and return on equity (ROE) at -308.65%. Stock’s beta reads 0.57. Stock has a price to book (P/B) ratio of 0.59. Its return on asset (ROA) is -172.77% on average.